The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors
Official Title: A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors
Study ID: NCT01733004
Brief Summary: This study is a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3" design, evaluating MM-141 at varying dose levels and frequencies.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
, Marietta, Georgia, United States
, Boston, Massachusetts, United States
, Detroit, Michigan, United States
, Villejuif, , France
Name: Chrystal Louis, MD, MPH
Affiliation: Merrimack Pharmaceuticals
Role: STUDY_DIRECTOR